Artiva Biotherapeutics reported cash from operations of -$20.30M and free cash flow of -$20.66M for the quarter ended Jun 2026, up 11.7% year over year. This cash flow statement covers 13 quarters of results from Jun 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||
| Net Income | -11.31M | 11.23M | -11.39M | -13.84M | -15.51M | -16.49M | -16.09M | -20.31M | -21.25M | -21.52M | -20.77M | -23.52M | -25.00M |
| Share-based Compensation | 1.37M | 1.39M | 1.41M | 1.48M | 1.91M | 2.18M | 2.05M | 1.55M | 1.63M | 1.59M | 4.06M | 3.71M | |
| Cash from Operations | -10.75M | -10.68M | -15.09M | -13.69M | -11.61M | -14.65M | -19.84M | -22.98M | -19.20M | -14.78M | -21.00M | -20.30M | |
| Depreciation, Depletion & Amortization | |||||||||||||
| Amortizatization of Intangibles | 0.28M | 0.37M | 0.27M | 0.66M | 1.04M | 0.72M | 0.51M | 0.36M | 0.29M | 0.20M | 0.12M | ||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.56M | 0.59M | 0.59M | 0.60M | 0.63M | 0.61M | 0.63M | 0.64M | 0.66M | 0.67M | 0.67M | 0.69M | |
| Change in Working Capital | |||||||||||||
| Change in Receivables | -0.08M | -1.10M | -0.21M | -0.25M | -0.57M | ||||||||
| Change in Account Payables | 1.59M | -1.92M | 0.85M | -0.95M | 0.70M | -0.08M | 0.04M | -0.21M | -0.44M | -0.15M | 1.81M | -0.78M | |
| Change in Accured Expenses | -0.36M | 0.14M | -3.04M | 0.27M | 3.10M | -0.99M | -0.93M | -0.55M | 1.12M | 2.37M | -4.00M | 4.02M | |
| Other Working Capital Changes | 0.77M | -0.22M | 0.94M | -0.30M | 1.50M | -0.18M | 0.75M | 2.86M | -0.19M | -1.89M | -2.63M | 0.78M | |
| Investing Activities | |||||||||||||
| Capital Expenditures | 0.18M | 0.64M | -0.03M | 0.51M | 0.10M | 0.06M | 0.88M | 0.68M | 0.60M | 0.42M | 0.30M | 0.36M | |
| Change in Acquisitions & Divestments | 12.00M | 12.80M | 16.00M | 14.00M | 12.40M | 13.95M | 29.00M | 28.25M | 29.62M | 24.00M | 22.00M | 18.00M | |
| Cash from Investing Activities | -0.49M | -2.67M | 9.78M | 1.35M | -130.63M | -0.97M | 9.97M | 21.12M | 16.28M | 16.04M | 15.32M | 17.59M | |
| Financing Activities | |||||||||||||
| Other financing activities | 0.01M | 0.02M | 0.14M | ||||||||||
| Change in Capital Stock | |||||||||||||
| Net Shares Issued and Repurchased | 1.06M | 0.15M | 1.56M | 0.11M | |||||||||
| Misc. | |||||||||||||
| Cash from Financing Activities | 23.43M | 0.96M | 163.87M | -0.03M | 0.24M | -0.07M | -0.04M | -0.12M | -0.11M | 283.27M | |||
| Change in Cash | 12.19M | -12.38M | -5.30M | -13.95M | 21.63M | -15.65M | -9.63M | -1.93M | -2.96M | 1.19M | -5.75M | 280.50M | |
| Free Cash Flow | -10.93M | -11.31M | -15.05M | -14.20M | -11.71M | -14.71M | -20.72M | -23.67M | -19.80M | -15.20M | -21.30M | -20.66M | |
| Net Cash Flow | 12.19M | -12.38M | -5.30M | -12.34M | 21.63M | -15.65M | -9.63M | -1.93M | -2.96M | 1.14M | -5.80M | 280.55M |